Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series

Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields (TTFields) therapy approved in the United States for n...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansstas, George, Tran, David D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Published online: January, 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748800/
https://www.ncbi.nlm.nih.gov/pubmed/26889149
http://dx.doi.org/10.1159/000442196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748800/
https://www.ncbi.nlm.nih.gov/pubmed/26889149
http://dx.doi.org/10.1159/000442196

Ejemplares similares